Breaking News

Financial Report: Catalent 1Q12

Oral Technologies revenue up 13%

Catalent 1Q12

1Q Revenues: $410.5 million (+8%)

1Q Loss: $5.2 million (loss of $28.8 million 1Q11)

Comments: Oral Technologies revenue was $274.9 million (+13%), driven by continued demand for Rx softgel products and controlled release products. Sterile Technologies revenue was $52.7 million (-2%), due to lower flu and non-flu demand. Packaging Services revenue was $40.7 million (-12%), impacted by property and casualty loss at the company’s UK-based commercial packaging facility. Development & Clinical Services revenue was $47.6 million (+10%), attributed to a favorable product mix, expanded analytical services capabilities, and Clinical Services revenue (+13%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters